Mizuho Maintains Buy on ResMed, Raises Price Target to $215

ResMed Inc. -0.58% Pre

ResMed Inc.

RMD

205.96

205.96

-0.58%

0.00% Pre

Mizuho analyst Anthony Petrone maintains ResMed (NYSE: RMD) with a Buy and raises the price target from $195 to $215.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via